New combo therapy shows promise for Hard-to-Treat cancers
NCT ID NCT02964013
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This early-phase study tested a new drug called vibostolimab, either alone or combined with pembrolizumab (and sometimes chemotherapy), in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drugs could shrink tumors. The study is complete, and results help guide future research on these combinations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.